Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Shares of Japanese pharma major Takeda were up 2.6% at 4,664 yen today, after it announced positive top-line results from its randomized, double-blind, placebo-controlled, multiple-dose Phase IIb trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. 12 September 2023
Pharmaceutical
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance (AMR). 12 September 2023
Biosimilars
South Korea's Celltrion Healthcare has launched a campaign to celebrate a decade of continuous biosimilar innovation in Europe. 11 September 2023
Biotechnology
Japan’s Daiichi Sankyo has presented impressive results on patritumab deruxtecan (HER3-DXd), a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC). 11 September 2023
Biotechnology
Early lung cancer data show a promising treatment effect for a checkpoint blocker plus antibody-drug conjugate (ADC) combo. 11 September 2023
Biosimilars
Samsung Bioepis has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Johnson & Johnson subsidiary Janssen’s Stelara (ustekinumab). 11 September 2023
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted for review a new drug application (NDA) for momelotinib, filed by UK pharma major GSK. 11 September 2023
Biotechnology
Japanese mid-size drugmaker Otsuka Pharmaceutical has inked a deal with ShapeTX, a specialist in programmable medicines. 8 September 2023
Biotechnology
Japanese pharma major Daiichi Sankyo today announced that the primary endpoint was achieved in a Phase III trial of a booster vaccination with DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19) being developed in Japan (in a booster vaccination trial). 7 September 2023
Pharmaceutical
Japanese pharma major Astellas Pharma revealed that it has requested that the Court dismiss the company’s lawsuit challenging the constitutionality of certain provisions of the US government’s Inflation Reduction Act (IRA). 7 September 2023
Biotechnology
Following its first Chinese approval earlier this year, a next generation BTK blocker, Calquence (acalabrutinib), has picked up another nod in the country. 4 September 2023
Biotechnology
US synthetic DNA producer Twist Bioscience today announced a drug discovery agreement with Japan’s Ono Pharmaceutical to discover and develop novel antibodies for the treatment of autoimmune diseases. 31 August 2023
Biotechnology
Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy designations (BTDs) in the USA. 31 August 2023
Pharmaceutical
Privately-held Danish company MC2 Therapeutics today announced an agreement under which a Huadong Medicine unit has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream for the treatment of plaque psoriasis. 31 August 2023
Pharmaceutical
Japanese drugmaker Kyowa Kirin has received approval in its home country for a higher-dose formulation of its oral calcimimetics agent Orkedia (evocalcet). 30 August 2023
Pharmaceutical
Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, has announced that its FGFR inhibitor Lytgobi (futibatinib) has now been listed on the National Health Insurance (NHI) reimbursement price list. 30 August 2023
Biotechnology
US antibody-drug conjugates (ADCs) developer ImmunoGen has entered into an exclusive collaboration with Takeda Pharmaceutical to develop and commercialize Elahere (mirvetuximab soravtansine-gynx; MIRV) in Japan. 29 August 2023
Pharmaceutical
A new discovery and development collaboration has been agreed between Boston, USA-based Verastem Oncology and Shanghai's GenFleet Therapeutics. 29 August 2023
Pharmaceutical
Japanese drugmaker Otsuka Holdings subsidiary Taiho Pharmaceutical has entered into an option and license agreement with French biotech firm Phost’in Therapeutics, through which Taiho will gain option rights to in-license PhOx430, a first-in-class small molecule targeting GnT-V (nacetylglucosaminyltransferase-V). 29 August 2023
Biotechnology
An update on the Phase III LEAP-010 trial evaluating Eisai Lenvima (lenvatinib) plus Merck & Co’s Keytruda (pembrolizumab), as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1, was announced today. 25 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze